CENTRAL LABORATORY FOR VIRAL ACTIVATION TRANSFUSION

病毒激活输血中心实验室

• 批准号: 2803538
• 负责人: MICHAEL Paul BUSCH
• 金额: --
• 依托单位: BLOOD CENTERS OF THE PACIFIC
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2803538
• 关键词: HIV infections; blood filtration; cytomegalovirus; gamma radiation; human immunodeficiency virus 1; human subject; leukocyte activation /transformation; leukocyte transfusion; prognosis

The initial goal is to determine if viral activation occurs following blood transfusion and if leukocyte depletion or irradiation can prevent it. Both clinical and laboratory data will be collected. Both CMV and HIV-1 will be studied in HIV-1 infected transfusion recipients. The initial part of the study will enroll 330 HIV-1 infected patients at the time they are scheduled for transfusion. The effects of gamma irradiation and leukocyte reduction on CMV and HIV viremia will be examined using quantitative PCR and viral culture. The effect of repeated transfusion, if needed, will also be assessed. Clinical data will be collected on transfused patients. The study will be a multicenter study of 330 HIV-1 infected patients with CD4 counts below 250 cell/cc3. Patients scheduled for transfusion will be entered into the study at the time of their first transfusion and randomized to one of three arms: to receive unmanipulated blood components, filtered blood, or irradiated blood. Patients will receive blood components treated in this way for a period of one to two years. Blood samples will be taken from the individuals before transfusion and at varying intervals after transfusion. These samples will be studied using the polymerase chain reaction technology and quantitative culture to determine if activation of CMV or HIV-1 occurs following transfusion. These tests will also be done at intervals when the patient is not being transfused to determine the values at baseline. These individuals will also be tested for a number of other immunological markers as determined by the steering committee. The individuals will also be examined by a physician regularly and monitored for the presence of opportunistic infection.

最初的目标是确定病毒是否在以下情况下激活 输血和白细胞耗尽或辐射是否可以防止 它。临床和实验室数据都将被收集。CMV和 HIV-1将在感染HIV-1的输血接受者中进行研究。这个 该研究的初始部分将招募330名HIV-1感染者 他们被安排输血的时间。伽马辐射的效应 对巨细胞病毒和艾滋病毒病毒血症的白细胞减少将使用 定量聚合酶链反应和病毒培养。反复输血的效果，如果 需要，也将进行评估。临床数据将在以下日期收集 输血病人。 这项研究将是一项多中心研究，对象为330名感染HIV-1的患者 CD4细胞数低于250cell/cc3。计划输血的患者将被 在他们第一次输血时进入研究并 随机分成三组之一：接受未经处理的血液 成分、过滤血液或辐照血液。患者将收到 血液成分以这种方式处理一到两年。 在输血前和输血时，会从病人身上抽取血液样本 输液后间隔时间不同。这些样本将使用以下方法进行研究 聚合酶链式反应技术与定量培养 确定输血后是否发生CMV或HIV-1的激活。 这些检查也将在患者不接受治疗的时间间隔进行 输液用于确定基线上的值。这些人将 也可以检测出其他一些免疫标志物 由指导委员会提供。这些个人还将接受一项 医生定期并监测是否存在机会主义 感染。